Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
One-year open-label deferasirox trial in low- and intermediate-1-risk MDS with transfusion-dependent iron overload
2006-003971-11Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deferasirox in myelodysplastic syndrome (MDS) and iron overload, sponsored by Novartis. Primary endpoints: Serum ferritin and Safety and tolerability of ICL670. Started Dec 2006; status: completed.
02
Drugs
deferasirox
03
Conditions
myelodysplastic syndrome (MDS)iron overload
Beyond the preview
Go deeper on 2006-003971-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003971-11.